Christopher Haqq, M.D., Ph.D.

Christopher Haqq, M.D., Ph.D.

Executive Vice President, Head of Research and Development and Chief Medical OfficeratElicio Therapeutics· In proxies 2022–2025

Pay in FY2025+16% from the year before · Elicio Therapeutics stock +56.1% the same year

Christopher Haqq, M.D., Ph.D. was paid $1.1M in FY2025 (Dec), up 16%. Elicio Therapeutics stock rose 56.1% that year.

Pay$100 in the stock at the end of FY21 → $27
Pay is from the Summary Compensation Table of each Elicio Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Elicio TherapeuticsPublic company · 4 yr
    • Executive Vice President, Head of Research and Development and Chief Medical Officer2022 – Present · 4 yrStock in role -93%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?